Patients with Friedreich’s ataxia in Ireland are facing delays in accessing the medication Skyclarys, despite its reimbursement approval. The drug, which is used to treat the condition, has been approved for funding by the healthcare system, but patients are reporting difficulties in obtaining it. Some have said they are waiting several weeks for their prescriptions to be processed.
The delay has raised concerns among patient advocacy groups, who warn that the wait could impact treatment outcomes. Friedreich’s ataxia is a rare genetic disorder that affects the nervous system, leading to progressive loss of motor skills. Skyclarys is one of the few available treatments for the condition.
Healthcare officials have not yet provided a timeline for resolving the delays. Some patients have turned to private funding to ensure they can access the medication. The situation highlights ongoing challenges in the availability of rare disease treatments within the public healthcare system.
The issue has sparked calls for greater transparency and faster processing of medication requests for patients with rare conditions.
